Newsletter | May 16, 2023

05.16.23 -- Increase Drug Development Efficiency Using Nanotechnology

Nanoscale Technology's Potential: A Fireside Chat With Industry Leaders

Nanoform's CEO, Professor Edward Hæggström, and Shawn Davies, head of drug delivery, biopharmaceuticals development, AstraZeneca — a long term partner of Nanoform — discuss the potential of nanoscale medicines and delivery devices to benefit patients.

Partnering On An Innovative Hydrogel-Based Treatment For Glioblastoma

Glioblastoma multiforme (GBM) is the most common type of malignant primary brain tumor. It is difficult to treat and has a high risk of recurrence after surgery, placing efficacious treatments in high demand. Explore new possibilities for increased dosing capabilities and diffusion across the brain parenchyma offered by nanoformed APIs.

Using Nanotechnology To Increase Drug Development Efficiency

The low-hanging fruit of drug development — simple compounds — have mainly been used up, prompting companies to focus on more complex molecules. Yet most of these exhibit solubility and bioavailability challenges. Discover how nanoforming drug particles to below 100 nm could help.

Bionanoparticle Technology

Nanoform’s proprietary bionanoparticle technology can deliver large molecule drug particles as small as 50 nm while retaining biological activity. This doesn't only enable more patient-friendly approaches to drug delivery, but also potentially higher loads of active ingredients.

Request Information
Small Molecule Capacity Update: March 2023

Sergie Letser, VP U.S. business development, presents an overview of Nanoform’s award winning Controlled Expansion of Supercritical Solutions (CESS®) technology, which solves solubility, bioavailability, and formulation challenges in development.

Request Information